UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/727,000	12/02/2003	Randall K. Ribaudo	4239-67022-01	5472
	7590 05/28/200 SPARKMAN, LLP	EXAMINER		
121 S.W. SALN		SCHWADRON, RONALD B		
SUITE #1600 PORTLAND, O	OR 97204-2988		ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			05/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	A	TTORNEY DOCKET NO.
10727000	12/2/2003	RIBAUDO ET AL.	4239-67022-01	
		EXAMINER		
KLARQUIST SPARKMAN, LLP 121 S.W. SALMON STREET SUITE #1600 PORTLAND, OR 97204-2988			Ron Schwadron, Ph.D.	
			ART UNIT	PAPER

DATE MAILED:

1644

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

200805

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

All Figures with amino acid sequences need to include the SEQ ID. Number for said sequence in the Figure itself or in the Brief Description of the Drawing section wherein said Figure is described. The nucleic acid sequence on page 17, line 2 appears to be listed in the 3' to 5' direction wherein 37 CFR 1.822(c)(5) requires that all nucleic acid sequences be listed in the 5" to 3" direction.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/Ron Schwadron, Ph.D./ Primary Examiner Art Unit 1644

> /Ron Schwadron, Ph.D./ Primary Examiner, Art Unit 1644